Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis.


Journal

Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511

Informations de publication

Date de publication:
17 07 2020
Historique:
received: 21 08 2019
accepted: 01 06 2020
entrez: 18 7 2020
pubmed: 18 7 2020
medline: 11 8 2020
Statut: ppublish

Résumé

The tumor microenvironment plays a critical regulatory role in cancer progression, especially in central nervous system metastases. Cancer cells within the cerebrospinal fluid (CSF)-filled leptomeninges face substantial microenvironmental challenges, including inflammation and sparse micronutrients. To investigate the mechanism by which cancer cells in these leptomeningeal metastases (LM) overcome these constraints, we subjected CSF from five patients with LM to single-cell RNA sequencing. We found that cancer cells, but not macrophages, within the CSF express the iron-binding protein lipocalin-2 (LCN2) and its receptor SCL22A17. These macrophages generate inflammatory cytokines that induce cancer cell LCN2 expression but do not generate LCN2 themselves. In mouse models of LM, cancer cell growth is supported by the LCN2/SLC22A17 system and is inhibited by iron chelation therapy. Thus, cancer cells appear to survive in the CSF by outcompeting macrophages for iron.

Identifiants

pubmed: 32675368
pii: 369/6501/276
doi: 10.1126/science.aaz2193
pmc: PMC7816199
mid: NIHMS1652359
doi:

Substances chimiques

LCN2 protein, human 0
Lipocalin-2 0
Iron E1UOL152H7

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

276-282

Subventions

Organisme : NCI NIH HHS
ID : U2C CA233284
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA245499
Pays : United States
Organisme : NCI NIH HHS
ID : L30 CA189044
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA220508
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Références

J Neuroendocrinol. 2013 Mar;25(3):271-80
pubmed: 23046379
Cell. 2018 Aug 23;174(5):1293-1308.e36
pubmed: 29961579
Cell Host Microbe. 2016 Apr 13;19(4):455-69
pubmed: 27078067
Nat Rev Cancer. 2013 May;13(5):342-55
pubmed: 23594855
Cell Metab. 2016 Dec 13;24(6):807-819
pubmed: 27866838
Neuro Oncol. 2012 Jan;14(1):43-52
pubmed: 21993441
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
Cell. 2005 Dec 29;123(7):1293-305
pubmed: 16377569
Mol Cell Biol. 2012 Oct;32(19):3938-48
pubmed: 22851691
Neurol Clin. 2003 Feb;21(1):25-66
pubmed: 12690644
Trends Immunol. 2011 Jun;32(6):241-7
pubmed: 21514223
Mol Cell. 2002 Nov;10(5):1045-56
pubmed: 12453413
Sci Signal. 2016 Jun 28;9(434):ra64
pubmed: 27353364
Int J Physiol Pathophysiol Pharmacol. 2018 Apr 20;10(2):105-114
pubmed: 29755643
Nat Rev Immunol. 2008 Dec;8(12):958-69
pubmed: 19029990
Cell. 2006 Jan 27;124(2):263-6
pubmed: 16439202
Mol Cell. 2002 Nov;10(5):1033-43
pubmed: 12453412
Exp Neurol. 2015 Nov;273:57-68
pubmed: 26247808
Blood. 1994 Feb 1;83(3):799-807
pubmed: 8298140
Oncoimmunology. 2017 Dec 22;7(3):e1408751
pubmed: 29399416
PLoS One. 2016 Nov 2;11(11):e0166164
pubmed: 27806101
Cell. 2017 Mar 9;168(6):1101-1113.e13
pubmed: 28283064
Nat Commun. 2014 Sep 17;5:4952
pubmed: 25229625
Nature. 2004 Dec 16;432(7019):917-21
pubmed: 15531878
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Cell Rep. 2016 Oct 11;17(3):684-696
pubmed: 27732846
Nature. 2017 Mar 16;543(7645):385-390
pubmed: 28273060
J Biol Chem. 1995 Sep 22;270(38):22565-70
pubmed: 7545679
Cell. 2016 Oct 6;167(2):457-470.e13
pubmed: 27667687
J Cancer Res Clin Oncol. 2010 Nov;136(11):1729-35
pubmed: 20204406
J Clin Invest. 2004 May;113(9):1271-6
pubmed: 15124018

Auteurs

Yudan Chi (Y)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Jan Remsik (J)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Vaidotas Kiseliovas (V)

Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Camille Derderian (C)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Ugur Sener (U)

Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Majdi Alghader (M)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Fadi Saadeh (F)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Katie Nikishina (K)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Tejus Bale (T)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Christine Iacobuzio-Donahue (C)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Tiffany Thomas (T)

Department of Pathology and Cell Biology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.

Dana Pe'er (D)

Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Linas Mazutis (L)

Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Adrienne Boire (A)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. boirea@mskcc.org.
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH